Results 71 to 80 of about 527 (153)

Novel drugs approved by the EMA, the FDA and the MHRA in 2024: A year in review

British Journal of Pharmacology, Volume 182, Issue 7, Page 1416-1445, April 2025.
Abstract In the past year, the European Medicines Agency (EMA), the Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) authorised 53 novel drugs. While the 2024 harvest is not as rich as in 2023, when 70 new chemical entities were approved, the number of ‘orphan’ drug authorisations in 2024 (21) is ...
Stavros Topouzis, Andreas Papapetropoulos, Steve P. H. Alexander, Miriam Cortese‐Krott, Dave A. Kendall, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Mauro M. Teixeira, Nathalie Vergnolle, Xin Wang, Péter Ferdinandy   +16 more
wiley   +1 more source

Stellenwert von Piperacillin/Tazobactam bei Patienten mit Blutstrominfektionen durch Ampicillin/Sulbactam-resistente nicht-Extended-Spektrum Betalaktamase-produzierende Escherichia coli: eine retrospektive Kohortenstudie [PDF]

Bakteriämien, der kulturelle Nachweis von Bakterien im Blutkreislauf, mit zusätzlich klinischen Zeichen einer Infektion stellen ein bedeutendes Gesundheitsproblem weltweit dar.
Paulussen, Emilia
core   +1 more source

Antimicrobial Challenge in Acute Care Surgery [PDF]

, 2022
The burden of infections in acute care surgery (ACS) is huge. Surgical emergencies alone account for three million admissions per year in the United States (US) with estimated financial costs of USD 28 billion per year.
Bianchi G., Carra M. C., de'Angelis G. L., de'Angelis N., Schena C. A.   +4 more
core   +2 more sources

Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions [PDF]

[Objectives] To analyse the impact of the most clinically relevant β-lactamases and their interplay with low outer membrane permeability on the activity of cefiderocol, ceftazidime/avibactam, aztreonam/avibactam, cefepime/enmetazobactam, cefepime ...
Blanco-Martín, Tania, Alonso-García, Isaac, González-Pinto, Lucía, Outeda-García, Michelle, Guijarro-Sánchez, Paula, López-Hernández, Inmaculada, Perez-Vazquez, Maria, Aracil, Belen, López-Cerero, Lorena, Fraile-Ribot, Pablo, Oliver, Antonio, Vázquez-Ucha, Juan Carlos, Beceiro, Alejandro, Bou, Germán, Arca-Suárez, Jorge, GEMARA/SEIMC-CIBERINFEC Study Group on the activity and resistance mechanisms to new β-lactams and β-lactamase inhibitors (PROTECT)   +15 more
core   +2 more sources

Method Development and Validation for the Simultaneous Estimation of Cefepime and Enmetazobactam in Bulk and Pharmaceutical Dosage form by RP-HPLC Method

A rapid, sensitive, and high precise reverse-phase high-performance liquid chromatography (RP-HPLC) method was developed for the simultaneous quantification of Cefepime and Enmetazobactam using a Waters HPLC system. Chromatographic separation was achieved on a Inertsil ODS C18 column (250 × 4.6 mm, 5 µm particle size) maintained at ambient temperature.
V. Vijaya*, K Suvarna, Dr. P V Madhavi Latha, Dr. P Uma Devi
  +4 more sources

HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF ENMETAZOBACTAM AND CEFEPIME [PDF]

The present study aimed to develop and validate a simple, precise, accurate, and robust reverse-phase high-performance liquid chromatography (RP-HPLC) method for the simultaneous estimation of Enmetazobactam (EMB) and Cefepime (CFP) in bulk and ...
Nidhi Sahu, Udit Narain Soni
core   +4 more sources

Spontaneous bacterial peritonitis due to carbapenemase-producing Enterobacteriaceae: Etiology and antibiotic treatment [PDF]

, 2020
Carbapenem antibiotics were first introduced in the 1980s and have long been considered the most active agents for the treatment of multidrug-resistant gram-negative bacteria.
Alfieri A., Di Franco S., Fiore M., Leone S., Martora F., Pace M. C., Passavanti M. B., Petrou S.   +7 more
core   +1 more source

Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii and Stenotrophomonas maltophilia: a systematic review and meta-analysis [PDF]

, 2023
Background Cefiderocol is a last resort option for carbapenem-resistant (CR) Gram-negative bacteria, especially metallo-β-lactamase (MBL)-producing Pseudomonas aeruginosa and CR Acinetobacter baumannii.
Karakonstantis, S., Kritsotakis, E.I., Rousaki, M., Vassilopoulou, L.   +3 more
core   +1 more source

Boronate-Based Inhibitors of Penicillin-Binding Proteins: An Underestimated Avenue for Antibiotic Discovery? [PDF]

Penicillin-binding proteins (PBPs) are essential enzymes involved in bacterial cell wall biosynthesis and represent the primary targets of β-lactam antibiotics.
Emilia Caselli, Fabio Prati, Luca Svolacchia Brusoni, Nicolo Santi, Valentina Villamil   +4 more
core   +1 more source

β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development

Pathogens
Antimicrobial resistance remains a public health problem of global concern with a great health and financial burden. Its recognition as a threat by political leadership has boosted the research and development of new antibiotics and particularly novel ...
Angeliki Katsarou, Panagiotis Stathopoulos, Iva D. Tzvetanova, Christina-Maria Asimotou, Matthew E. Falagas   +4 more
doaj   +1 more source